FAQs

Shares in Quest Diagnostics trade on the New York Stock Exchange under the symbol "DGX."

Fixed Income bonds trade over the counter.

Options on DGX shares are traded on the Chicago Board Options Exchange.

Our transfer agent is Computershare. They can be reached at:

Computershare
P.O. Box 43078
Providence, RI 02940-3078
Telephone inquiries: 800-622-6757 (US, Canada)
781-575-4735 (all other locations)

Overnight correspondence should be sent to:
Computershare
150 Royall St.,
Suite 101
Canton, MA 02021

Shareholder website

Shareholder online inquiries

https://www-us.computershare.com/investor/Contact

Book-entry form of registered ownership allows you to own shares without having paper stock certificates in your possession. You are the record owner and enjoy the same shareholder benefits as you would with certificated shares. If you have book-entry shares, you will receive a statement of your holdings on a yearly basis. You may, of course, request an additional statement at any time by contacting Computershare at 800-622-6757 (US, Canada) or 781-575-4735 (all other locations).

The Company’s Board of Directors on February 2, 2023 has authorized a 7.6% increase in its quarterly dividend from $0.66 to $0.71 per share. The increase is effective with the dividend payable on April 24, 2023 to shareholders of record of Quest Diagnostics common stock on April 10, 2023. With the increase, the annual dividend will be $2.84 per share. The company has raised its dividend annually since 2011.

The Company’s Board of Directors on August 14, 2023 declared a quarterly cash dividend of $0.71 per share, payable on October 23, 2023 to shareholders of record of Quest Diagnostics common stock on October 6, 2023.

Quest Diagnostics executed two-for-one stock splits on May 31, 2001 and on June 20, 2005.

Quest Diagnostics has credit rating relationships with Standard & Poor's, Moody's Investors Service and Fitch Ratings. Standard & Poor's rating is BBB+ with a stable outlook. Our Moody's current credit rating is Baa2 with a positive outlook. Our current credit rating with Fitch is BBB with a positive outlook.

Quest Diagnostics will release financial results for the third quarter ending September 30, 2023, on October 24, 2023.

Contact Investor Relations